Global Virology Market

Virology Comprehensive Study by Application (Medicine, Agriculture, Nanotechnology, Others), Diagnosis Test (Hepatitis B, Hepatitis C, HIV, Other), Disease (AIDS, Common Cold, Ebola, Genital Herpes, Influenza, Others) Players and Region - Global Market Outlook to 2027

Virology Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 5.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Virology?
A principal department of virology is virus classification. Virology is the scientific learn about of viruses – submicroscopic, parasitic organisms of genetic cloth contained in a protein coat and virus-like agents. It focuses on the following components of viruses: their structure, classification and evolution, their methods to infect and take advantage of host cells for reproduction, their interplay with host organism physiology and immunity, the illnesses they cause, the methods to isolate and lifestyle them, and their use in lookup and therapy. Virology is a subfield of microbiology. Virology is the scientific self-discipline involved with the learn about of the biology of viruses and viral diseases, which include the distribution, biochemistry, physiology, molecular biology, ecology, evolution and scientific elements of viruses.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
CAGR5.1%


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Virology market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GSK (United Kingdom), Pfizer (United States), AbbVie's (United States), Gilead Sciences (United States), Takeda Pharmaceuticals (Japan), Kineta, Inc. (United States), Cyclacel Pharmaceuticals (United States), Novavax, Inc. (United States), AllCells (United States) and Nektar Therapeutics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are RocketVax (Switzerland), Istari Oncology, Inc. (United States) and ATRIVA (Germany).

Segmentation Overview
AMA Research has segmented the market of Global Virology market by , Application (Medicine, Agriculture, Nanotechnology and Others) and Region.

On the basis of geography, the market of Virology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnosis Test, the sub-segment i.e. Hepatitis B will boost the Virology market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease, the sub-segment i.e. AIDS will boost the Virology market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In 2022 AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder.
In 2022, Takeda introduced that it has acquired manufacturing and advertising approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for major and booster immunization in folks aged 18 and older. Novavax licensed and transferred its manufacturing applied sciences to allow Takeda to improve and manufacture the vaccine at its facility in Hikari. Takeda will start distribution of Nuvaxovid doses bought by using the Government of Japan as quickly as possible.
The recommendations have been built for distribution and implementation at the laboratory level. Larger gadgets (divisions, departments, schools, and colleges, etc.) normally have insurance policies masking a subset of what is mentioned here. However, having special and customized files approves PIs to tackle laboratory-specific troubles as properly as to include their very own special mentoring style. It additionally permits the individualized hints to be posted on a laboratory Web web page (either interior or publicly available) or server for effortless get right of entry to and updating.

Market Drivers
  • Rising Public Awareness on Campaigns Diseases and Modern Technologies for Identifying and Treating Viral Illness

Opportunities
  • Healthcare Infrastructure
  • Facilitated Diagnostics
  • Growing affordability of Diagnostic tests for Viral Diseases

Restraints
  • Virus causes a wide range of diseases which include HIV, chickenpox, and influenza
  • Viruses have the ability to replicate and thus causes dead diseases like HIV


Key Target Audience
Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Application
  • Medicine
  • Agriculture
  • Nanotechnology
  • Others
By Diagnosis Test
  • Hepatitis B
  • Hepatitis C
  • HIV
  • Other

By Disease
  • AIDS
  • Common Cold
  • Ebola
  • Genital Herpes
  • Influenza
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Public Awareness on Campaigns Diseases and Modern Technologies for Identifying and Treating Viral Illness
    • 3.3. Market Trends
      • 3.3.1. Notable advances in Nanotechnology, Nanostructure-based electrical Sensors have been emerged as promising Platforms for real-time, sensitive detection of numerous Bioanalytes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Virology, by Application, Diagnosis Test, Disease and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Virology (Value)
      • 5.2.1. Global Virology by: Application (Value)
        • 5.2.1.1. Medicine
        • 5.2.1.2. Agriculture
        • 5.2.1.3. Nanotechnology
        • 5.2.1.4. Others
      • 5.2.2. Global Virology by: Diagnosis Test (Value)
        • 5.2.2.1. Hepatitis B
        • 5.2.2.2. Hepatitis C
        • 5.2.2.3. HIV
        • 5.2.2.4. Other
      • 5.2.3. Global Virology by: Disease (Value)
        • 5.2.3.1. AIDS
        • 5.2.3.2. Common Cold
        • 5.2.3.3. Ebola
        • 5.2.3.4. Genital Herpes
        • 5.2.3.5. Influenza
        • 5.2.3.6. Others
      • 5.2.4. Global Virology Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Virology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GSK (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie's (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Gilead Sciences (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Takeda Pharmaceuticals (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kineta, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cyclacel Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novavax, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AllCells (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Nektar Therapeutics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Virology Sale, by Application, Diagnosis Test, Disease and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Virology (Value)
      • 7.2.1. Global Virology by: Application (Value)
        • 7.2.1.1. Medicine
        • 7.2.1.2. Agriculture
        • 7.2.1.3. Nanotechnology
        • 7.2.1.4. Others
      • 7.2.2. Global Virology by: Diagnosis Test (Value)
        • 7.2.2.1. Hepatitis B
        • 7.2.2.2. Hepatitis C
        • 7.2.2.3. HIV
        • 7.2.2.4. Other
      • 7.2.3. Global Virology by: Disease (Value)
        • 7.2.3.1. AIDS
        • 7.2.3.2. Common Cold
        • 7.2.3.3. Ebola
        • 7.2.3.4. Genital Herpes
        • 7.2.3.5. Influenza
        • 7.2.3.6. Others
      • 7.2.4. Global Virology Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Virology: by Application(USD Million)
  • Table 2. Virology Medicine , by Region USD Million (2016-2021)
  • Table 3. Virology Agriculture , by Region USD Million (2016-2021)
  • Table 4. Virology Nanotechnology , by Region USD Million (2016-2021)
  • Table 5. Virology Others , by Region USD Million (2016-2021)
  • Table 6. Virology: by Diagnosis Test(USD Million)
  • Table 7. Virology Hepatitis B , by Region USD Million (2016-2021)
  • Table 8. Virology Hepatitis C , by Region USD Million (2016-2021)
  • Table 9. Virology HIV , by Region USD Million (2016-2021)
  • Table 10. Virology Other , by Region USD Million (2016-2021)
  • Table 11. Virology: by Disease(USD Million)
  • Table 12. Virology AIDS , by Region USD Million (2016-2021)
  • Table 13. Virology Common Cold , by Region USD Million (2016-2021)
  • Table 14. Virology Ebola , by Region USD Million (2016-2021)
  • Table 15. Virology Genital Herpes , by Region USD Million (2016-2021)
  • Table 16. Virology Influenza , by Region USD Million (2016-2021)
  • Table 17. Virology Others , by Region USD Million (2016-2021)
  • Table 18. South America Virology, by Country USD Million (2016-2021)
  • Table 19. South America Virology, by Application USD Million (2016-2021)
  • Table 20. South America Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 21. South America Virology, by Disease USD Million (2016-2021)
  • Table 22. Brazil Virology, by Application USD Million (2016-2021)
  • Table 23. Brazil Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 24. Brazil Virology, by Disease USD Million (2016-2021)
  • Table 25. Argentina Virology, by Application USD Million (2016-2021)
  • Table 26. Argentina Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 27. Argentina Virology, by Disease USD Million (2016-2021)
  • Table 28. Rest of South America Virology, by Application USD Million (2016-2021)
  • Table 29. Rest of South America Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 30. Rest of South America Virology, by Disease USD Million (2016-2021)
  • Table 31. Asia Pacific Virology, by Country USD Million (2016-2021)
  • Table 32. Asia Pacific Virology, by Application USD Million (2016-2021)
  • Table 33. Asia Pacific Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 34. Asia Pacific Virology, by Disease USD Million (2016-2021)
  • Table 35. China Virology, by Application USD Million (2016-2021)
  • Table 36. China Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 37. China Virology, by Disease USD Million (2016-2021)
  • Table 38. Japan Virology, by Application USD Million (2016-2021)
  • Table 39. Japan Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 40. Japan Virology, by Disease USD Million (2016-2021)
  • Table 41. India Virology, by Application USD Million (2016-2021)
  • Table 42. India Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 43. India Virology, by Disease USD Million (2016-2021)
  • Table 44. South Korea Virology, by Application USD Million (2016-2021)
  • Table 45. South Korea Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 46. South Korea Virology, by Disease USD Million (2016-2021)
  • Table 47. Taiwan Virology, by Application USD Million (2016-2021)
  • Table 48. Taiwan Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 49. Taiwan Virology, by Disease USD Million (2016-2021)
  • Table 50. Australia Virology, by Application USD Million (2016-2021)
  • Table 51. Australia Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 52. Australia Virology, by Disease USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Virology, by Application USD Million (2016-2021)
  • Table 54. Rest of Asia-Pacific Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 55. Rest of Asia-Pacific Virology, by Disease USD Million (2016-2021)
  • Table 56. Europe Virology, by Country USD Million (2016-2021)
  • Table 57. Europe Virology, by Application USD Million (2016-2021)
  • Table 58. Europe Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 59. Europe Virology, by Disease USD Million (2016-2021)
  • Table 60. Germany Virology, by Application USD Million (2016-2021)
  • Table 61. Germany Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 62. Germany Virology, by Disease USD Million (2016-2021)
  • Table 63. France Virology, by Application USD Million (2016-2021)
  • Table 64. France Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 65. France Virology, by Disease USD Million (2016-2021)
  • Table 66. Italy Virology, by Application USD Million (2016-2021)
  • Table 67. Italy Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 68. Italy Virology, by Disease USD Million (2016-2021)
  • Table 69. United Kingdom Virology, by Application USD Million (2016-2021)
  • Table 70. United Kingdom Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 71. United Kingdom Virology, by Disease USD Million (2016-2021)
  • Table 72. Netherlands Virology, by Application USD Million (2016-2021)
  • Table 73. Netherlands Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 74. Netherlands Virology, by Disease USD Million (2016-2021)
  • Table 75. Rest of Europe Virology, by Application USD Million (2016-2021)
  • Table 76. Rest of Europe Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 77. Rest of Europe Virology, by Disease USD Million (2016-2021)
  • Table 78. MEA Virology, by Country USD Million (2016-2021)
  • Table 79. MEA Virology, by Application USD Million (2016-2021)
  • Table 80. MEA Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 81. MEA Virology, by Disease USD Million (2016-2021)
  • Table 82. Middle East Virology, by Application USD Million (2016-2021)
  • Table 83. Middle East Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 84. Middle East Virology, by Disease USD Million (2016-2021)
  • Table 85. Africa Virology, by Application USD Million (2016-2021)
  • Table 86. Africa Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 87. Africa Virology, by Disease USD Million (2016-2021)
  • Table 88. North America Virology, by Country USD Million (2016-2021)
  • Table 89. North America Virology, by Application USD Million (2016-2021)
  • Table 90. North America Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 91. North America Virology, by Disease USD Million (2016-2021)
  • Table 92. United States Virology, by Application USD Million (2016-2021)
  • Table 93. United States Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 94. United States Virology, by Disease USD Million (2016-2021)
  • Table 95. Canada Virology, by Application USD Million (2016-2021)
  • Table 96. Canada Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 97. Canada Virology, by Disease USD Million (2016-2021)
  • Table 98. Mexico Virology, by Application USD Million (2016-2021)
  • Table 99. Mexico Virology, by Diagnosis Test USD Million (2016-2021)
  • Table 100. Mexico Virology, by Disease USD Million (2016-2021)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Virology: by Application(USD Million)
  • Table 112. Virology Medicine , by Region USD Million (2022-2027)
  • Table 113. Virology Agriculture , by Region USD Million (2022-2027)
  • Table 114. Virology Nanotechnology , by Region USD Million (2022-2027)
  • Table 115. Virology Others , by Region USD Million (2022-2027)
  • Table 116. Virology: by Diagnosis Test(USD Million)
  • Table 117. Virology Hepatitis B , by Region USD Million (2022-2027)
  • Table 118. Virology Hepatitis C , by Region USD Million (2022-2027)
  • Table 119. Virology HIV , by Region USD Million (2022-2027)
  • Table 120. Virology Other , by Region USD Million (2022-2027)
  • Table 121. Virology: by Disease(USD Million)
  • Table 122. Virology AIDS , by Region USD Million (2022-2027)
  • Table 123. Virology Common Cold , by Region USD Million (2022-2027)
  • Table 124. Virology Ebola , by Region USD Million (2022-2027)
  • Table 125. Virology Genital Herpes , by Region USD Million (2022-2027)
  • Table 126. Virology Influenza , by Region USD Million (2022-2027)
  • Table 127. Virology Others , by Region USD Million (2022-2027)
  • Table 128. South America Virology, by Country USD Million (2022-2027)
  • Table 129. South America Virology, by Application USD Million (2022-2027)
  • Table 130. South America Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 131. South America Virology, by Disease USD Million (2022-2027)
  • Table 132. Brazil Virology, by Application USD Million (2022-2027)
  • Table 133. Brazil Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 134. Brazil Virology, by Disease USD Million (2022-2027)
  • Table 135. Argentina Virology, by Application USD Million (2022-2027)
  • Table 136. Argentina Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 137. Argentina Virology, by Disease USD Million (2022-2027)
  • Table 138. Rest of South America Virology, by Application USD Million (2022-2027)
  • Table 139. Rest of South America Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 140. Rest of South America Virology, by Disease USD Million (2022-2027)
  • Table 141. Asia Pacific Virology, by Country USD Million (2022-2027)
  • Table 142. Asia Pacific Virology, by Application USD Million (2022-2027)
  • Table 143. Asia Pacific Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 144. Asia Pacific Virology, by Disease USD Million (2022-2027)
  • Table 145. China Virology, by Application USD Million (2022-2027)
  • Table 146. China Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 147. China Virology, by Disease USD Million (2022-2027)
  • Table 148. Japan Virology, by Application USD Million (2022-2027)
  • Table 149. Japan Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 150. Japan Virology, by Disease USD Million (2022-2027)
  • Table 151. India Virology, by Application USD Million (2022-2027)
  • Table 152. India Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 153. India Virology, by Disease USD Million (2022-2027)
  • Table 154. South Korea Virology, by Application USD Million (2022-2027)
  • Table 155. South Korea Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 156. South Korea Virology, by Disease USD Million (2022-2027)
  • Table 157. Taiwan Virology, by Application USD Million (2022-2027)
  • Table 158. Taiwan Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 159. Taiwan Virology, by Disease USD Million (2022-2027)
  • Table 160. Australia Virology, by Application USD Million (2022-2027)
  • Table 161. Australia Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 162. Australia Virology, by Disease USD Million (2022-2027)
  • Table 163. Rest of Asia-Pacific Virology, by Application USD Million (2022-2027)
  • Table 164. Rest of Asia-Pacific Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 165. Rest of Asia-Pacific Virology, by Disease USD Million (2022-2027)
  • Table 166. Europe Virology, by Country USD Million (2022-2027)
  • Table 167. Europe Virology, by Application USD Million (2022-2027)
  • Table 168. Europe Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 169. Europe Virology, by Disease USD Million (2022-2027)
  • Table 170. Germany Virology, by Application USD Million (2022-2027)
  • Table 171. Germany Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 172. Germany Virology, by Disease USD Million (2022-2027)
  • Table 173. France Virology, by Application USD Million (2022-2027)
  • Table 174. France Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 175. France Virology, by Disease USD Million (2022-2027)
  • Table 176. Italy Virology, by Application USD Million (2022-2027)
  • Table 177. Italy Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 178. Italy Virology, by Disease USD Million (2022-2027)
  • Table 179. United Kingdom Virology, by Application USD Million (2022-2027)
  • Table 180. United Kingdom Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 181. United Kingdom Virology, by Disease USD Million (2022-2027)
  • Table 182. Netherlands Virology, by Application USD Million (2022-2027)
  • Table 183. Netherlands Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 184. Netherlands Virology, by Disease USD Million (2022-2027)
  • Table 185. Rest of Europe Virology, by Application USD Million (2022-2027)
  • Table 186. Rest of Europe Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 187. Rest of Europe Virology, by Disease USD Million (2022-2027)
  • Table 188. MEA Virology, by Country USD Million (2022-2027)
  • Table 189. MEA Virology, by Application USD Million (2022-2027)
  • Table 190. MEA Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 191. MEA Virology, by Disease USD Million (2022-2027)
  • Table 192. Middle East Virology, by Application USD Million (2022-2027)
  • Table 193. Middle East Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 194. Middle East Virology, by Disease USD Million (2022-2027)
  • Table 195. Africa Virology, by Application USD Million (2022-2027)
  • Table 196. Africa Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 197. Africa Virology, by Disease USD Million (2022-2027)
  • Table 198. North America Virology, by Country USD Million (2022-2027)
  • Table 199. North America Virology, by Application USD Million (2022-2027)
  • Table 200. North America Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 201. North America Virology, by Disease USD Million (2022-2027)
  • Table 202. United States Virology, by Application USD Million (2022-2027)
  • Table 203. United States Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 204. United States Virology, by Disease USD Million (2022-2027)
  • Table 205. Canada Virology, by Application USD Million (2022-2027)
  • Table 206. Canada Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 207. Canada Virology, by Disease USD Million (2022-2027)
  • Table 208. Mexico Virology, by Application USD Million (2022-2027)
  • Table 209. Mexico Virology, by Diagnosis Test USD Million (2022-2027)
  • Table 210. Mexico Virology, by Disease USD Million (2022-2027)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Virology: by Application USD Million (2016-2021)
  • Figure 5. Global Virology: by Diagnosis Test USD Million (2016-2021)
  • Figure 6. Global Virology: by Disease USD Million (2016-2021)
  • Figure 7. South America Virology Share (%), by Country
  • Figure 8. Asia Pacific Virology Share (%), by Country
  • Figure 9. Europe Virology Share (%), by Country
  • Figure 10. MEA Virology Share (%), by Country
  • Figure 11. North America Virology Share (%), by Country
  • Figure 12. Global Virology share by Players 2021 (%)
  • Figure 13. Global Virology share by Players (Top 3) 2021(%)
  • Figure 14. Global Virology share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GSK (United Kingdom) Revenue: by Geography 2021
  • Figure 18. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer (United States) Revenue: by Geography 2021
  • Figure 20. AbbVie's (United States) Revenue, Net Income and Gross profit
  • Figure 21. AbbVie's (United States) Revenue: by Geography 2021
  • Figure 22. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 23. Gilead Sciences (United States) Revenue: by Geography 2021
  • Figure 24. Takeda Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Takeda Pharmaceuticals (Japan) Revenue: by Geography 2021
  • Figure 26. Kineta, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Kineta, Inc. (United States) Revenue: by Geography 2021
  • Figure 28. Cyclacel Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 29. Cyclacel Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 30. Novavax, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Novavax, Inc. (United States) Revenue: by Geography 2021
  • Figure 32. AllCells (United States) Revenue, Net Income and Gross profit
  • Figure 33. AllCells (United States) Revenue: by Geography 2021
  • Figure 34. Nektar Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Nektar Therapeutics (United States) Revenue: by Geography 2021
  • Figure 36. Global Virology: by Application USD Million (2022-2027)
  • Figure 37. Global Virology: by Diagnosis Test USD Million (2022-2027)
  • Figure 38. Global Virology: by Disease USD Million (2022-2027)
  • Figure 39. South America Virology Share (%), by Country
  • Figure 40. Asia Pacific Virology Share (%), by Country
  • Figure 41. Europe Virology Share (%), by Country
  • Figure 42. MEA Virology Share (%), by Country
  • Figure 43. North America Virology Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GSK (United Kingdom)
  • Pfizer (United States)
  • AbbVie's (United States)
  • Gilead Sciences (United States)
  • Takeda Pharmaceuticals (Japan)
  • Kineta, Inc. (United States)
  • Cyclacel Pharmaceuticals (United States)
  • Novavax, Inc. (United States)
  • AllCells (United States)
  • Nektar Therapeutics (United States)
Additional players considered in the study are as follows:
RocketVax (Switzerland) , Istari Oncology, Inc. (United States) , ATRIVA (Germany)
Select User Access Type

Key Highlights of Report


May 2022 159 Pages 50 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Virology Market Quantitative research analysis
Global Virology Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GSK (United Kingdom), Pfizer (United States), AbbVie's (United States), Gilead Sciences (United States), Takeda Pharmaceuticals (Japan), Kineta, Inc. (United States), Cyclacel Pharmaceuticals (United States), Novavax, Inc. (United States), AllCells (United States) and Nektar Therapeutics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Notable advances in Nanotechnology, Nanostructure-based electrical Sensors have been emerged as promising Platforms for real-time, sensitive detection of numerous Bioanalytes" is seen as one of major influencing trends for Virology Market during projected period 2021-2027.

Know More About Global Virology Market Report?

Have a Query? Click Here

Other Related Reports

Biotechnology Reagents & Kits Comprehensive Study by Type (Purification Kits, Amplification Kits, Detection Kits, Isolation Kits, Others), Micro-Organisms (Bacteria, Virus, Fungi, Parasites), Technol...
$ 3800
Virology Specimen Collection Comprehensive Study by Application (Diagnostics, Research), End-users (Hospitals & Clinics, Diagnostic Centers, Others), Samples (Blood Samples, Nasopharyngeal Samples, T...
$ 3500
Biotechnology Services Comprehensive Study by Application (Pharmaceutical, Clinical Trial, Healthcare Sectors), Technology (Tissue Engineering and Regeneration, PCR Technology, Nano Biotechnology, Ch...
$ 3500
NGS-Based RNA-Sequencing Comprehensive Study by Type (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Application (Cancer Biomarkers, Cancer Heterogeneity and Drug Resistance, ...
$ 3800
Microarray Analysis Comprehensive Study by Application (DNA Microarray Analysis, RNA Microarray Analysis, Protein Microarray Analysis), Components (Solution, Services), Techniques (Aggregation And No...
$ 3800
Protein Extracts Comprehensive Study by Type (Human Protein Extracts, Animal/Insect Protein Extracts, Plant Protein Extracts), Application (Food & Beverages, Pharmaceuticals, Cosmetics, Others), Natu...
$ 3800